Genetic Technologies Limited (AU:GTG) has released an update.
Genetic Technologies Limited is launching a clinical study to integrate its geneType Breast Cancer Risk Assessment Test into breast imaging centers in New York, Miami, and Houston, aiming to enhance personalized medicine and streamline patient care. The study, backed by leading clinicians, will evaluate the test’s effectiveness in identifying women at increased risk of breast cancer and improving adherence to screening protocols. This initiative promises to advance the precision medicine approach in breast cancer screening and risk reduction, potentially impacting the current addressable market of 68 million women in the U.S.
For further insights into AU:GTG stock, check out TipRanks’ Stock Analysis page.
